Dec 15 (Reuters) – Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor.
The oral drug, varegacestat, is being tested in patients with desmoid tumors, also known as aggressive fibromatosis or desmoid-type fibromatosis, that are aggressive non-metastatic soft tissue tumors that are prone to recurrence.
The trial showed varegacestat significantly improved progression-free survival compared with placebo, cutting the risk of disease progression or death by 84%.
Immunome plans to file for U.S. approval in the second quarter of 2026.
Shares of cancer drug developer were up 30% in premarket trading.
(Reporting by Siddhi Mahatole in Bengaluru)
